Foreign Manufacturing Cost-Savings Might Be Offset By Regulatory Due Diligence, FDA's Woodcock Cautions
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies may have more work down the line dealing with regulatory authorities if they manufacture products in foreign countries not following an accepted regulatory structure.
You may also be interested in...
FDA Inspection Growth In China Stymied By Visa Issues
The agency is waiting for approval to locate 10 new drug inspectors in China.
Foreign Regulator Exchange Program Contemplated By U.S. State Department
FDA has its own programs, but a State Department undersecretary said enhancing training at FDA could boost efforts to fight drug counterfeiting and diversion.
Foreign Regulator Exchange Program Contemplated By U.S. State Department
FDA has its own programs, but a State Department undersecretary said enhancing training at FDA could boost efforts to fight drug counterfeiting and diversion.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: